Trexquant Investment LP Increases Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Trexquant Investment LP grew its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 180.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 69,971 shares of the biopharmaceutical company's stock after acquiring an additional 45,005 shares during the quarter. Trexquant Investment LP owned about 0.12% of Agios Pharmaceuticals worth $2,299,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in AGIO. Vanguard Group Inc. grew its position in shares of Agios Pharmaceuticals by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock valued at $185,045,000 after buying an additional 85,339 shares during the last quarter. State Street Corp grew its holdings in shares of Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock worth $103,586,000 after purchasing an additional 216,484 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 0.5% during the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company's stock worth $60,326,000 after purchasing an additional 6,101 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in shares of Agios Pharmaceuticals by 19.7% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company's stock valued at $46,392,000 after purchasing an additional 172,180 shares during the last quarter. Finally, Fisher Asset Management LLC lifted its holdings in shares of Agios Pharmaceuticals by 12.3% in the 4th quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock valued at $31,567,000 after purchasing an additional 105,333 shares during the last quarter.

Remove Ads

Agios Pharmaceuticals Stock Up 5.5 %

NASDAQ:AGIO traded up $1.39 during midday trading on Friday, reaching $26.70. The stock had a trading volume of 592,295 shares, compared to its average volume of 711,070. The stock has a market cap of $1.53 billion, a P/E ratio of 2.35 and a beta of 0.83. The firm has a fifty day simple moving average of $31.39 and a two-hundred day simple moving average of $39.24. Agios Pharmaceuticals, Inc. has a 12-month low of $23.42 and a 12-month high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on AGIO. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price target on the stock. StockNews.com cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, February 14th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $56.57.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.93% of the stock is owned by insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.